2014 Life Sciences Outlook in Turkey

Rapid Economic Development and Healthcare Reforms Set the Stage for the Future
Share this:
     
Published: 4 Nov 2014

The Turkish pharmaceuticals segment is the 14th largest worldwide and the 6th largest in Europe, valued at $14.04 billion in 2013 and projected to grow at a CAGR of 9.1% from 2013 to 2018. Growth is driven by expanding public insurance, modernisation, prevalence of chronic diseases, increasing health awareness, and affluence. Market segmentation is based on products (e.g., over-the-counter, generic, and patented drugs) and therapeutic areas (e.g., antibiotics, anti-rheumatics, cardiovascular, analgesics, oncology, cough preparations, and central nervous system). The study provides a macroeconomic overview of Turkey’s mergers and acquisitions/investment trends, regulatory environment, revenue forecasts, key trends, and companies to watch.

  1.  
  2.  
  3.  
  4.  
  5.  
  6.  
  7.  
  8.  
  9.  
  10.  
  11.  
  12.  

Tools

Features of this research

SUBSCRIPTIONS

Help Desk

Full list of offices


For more information and general enquiries, contact Frost & Sullivan near you.

North America
tel: +1.877.463.7678

Select a location near you..